Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) PT at $57.20

Shares of Silence Therapeutics plc (NASDAQ:SLN) have been assigned an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $57.20.

A number of equities analysts recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Monday, December 9th. BMO Capital Markets reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Jefferies Financial Group initiated coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Morgan Stanley restated an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, October 8th.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors have recently made changes to their positions in SLN. Values First Advisors Inc. acquired a new stake in Silence Therapeutics during the third quarter worth about $56,000. Y Intercept Hong Kong Ltd lifted its holdings in shares of Silence Therapeutics by 22.9% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after acquiring an additional 3,923 shares during the period. Quarry LP acquired a new stake in shares of Silence Therapeutics during the 2nd quarter worth approximately $114,000. Marshall Wace LLP boosted its position in shares of Silence Therapeutics by 7.3% during the 2nd quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock worth $2,839,000 after acquiring an additional 10,206 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in Silence Therapeutics in the third quarter valued at approximately $207,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $6.74 on Friday. The company has a market cap of $201.73 million, a price-to-earnings ratio of -4.29 and a beta of 1.05. The firm has a 50-day moving average of $13.45 and a 200-day moving average of $16.97. Silence Therapeutics has a one year low of $5.81 and a one year high of $27.72.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.